Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:insulin |
| gptkbp:amendedBy |
asparagine at B3 replaced by lysine
lysine at B29 replaced by glutamic acid |
| gptkbp:approvalYear |
2004
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A10AB06
|
| gptkbp:brand |
gptkb:Apidra
|
| gptkbp:CASNumber |
207748-29-6
|
| gptkbp:developedBy |
gptkb:Sanofi
|
| gptkbp:eliminationHalfLife |
42 minutes
|
| gptkbp:hasMolecularFormula |
C258H384N64O78S6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Insulin glulisine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
lowers blood glucose
|
| gptkbp:onset |
gptkb:fire
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:product |
recombinant
|
| gptkbp:PubChem_CID |
16132451
|
| gptkbp:routeOfAdministration |
subcutaneous injection
intravenous injection |
| gptkbp:sideEffect |
gptkb:hypoglycemia
allergic reactions lipodystrophy |
| gptkbp:UNII |
GDT1G0A4F2
|
| gptkbp:usedFor |
gptkb:diabetes_mellitus_type_2
diabetes mellitus type 1 |
| gptkbp:bfsParent |
gptkb:insulin
|
| gptkbp:bfsLayer |
6
|